Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Ulrich Julius

Showing results (61-70 of 76) with videos related to

Pageof 8
Sort By:
Atherosclerosis. Supplements|November 4, 2017
Lipidological competence centres and networks: Future perspectives to improve healthcare of patients with disorders of lipid metabolismFranz Heigl, Tobias Pflederer, Volker Schettler, et al.
Therapeutic Apheresis and Dialysis : Official Peer-Reviewed Journal of the International Society for Apheresis, the Japanese Society for Apheresis, the Japanese Society for Dialysis Therapy|December 5, 2022
The German Lipoprotein Apheresis Registry-Summary of the ninth annual reportVolker J J Schettler, Christian Peter, Thomas Zimmermann, et al.
Hormone and Metabolic Research = Hormon- Und Stoffwechselforschung = Hormones Et Metabolisme|December 12, 2019
Metabolic and Non-Metabolic Peripheral Neuropathy: Is there a Place for Therapeutic Apheresis?Richard Straube, Gregor Müller, Karin Voit-Bak, et al.
Journal of Clinical Lipidology|June 3, 2017
Toward an international consensus-Integrating lipoprotein apheresis and new lipid-lowering drugsClaudia Stefanutti, Ulrich Julius, Gerald F Watts, et al.
Arteriosclerosis, Thrombosis, and Vascular Biology|July 16, 2016
Lipoprotein Apheresis for Lipoprotein(a)-Associated Cardiovascular Disease: Prospective 5 Years of Follow-Up and Apolipoprotein(a) CharacterizationEberhard Roeseler, Ulrich Julius, Franz Heigl, et al.
Hormone and Metabolic Research = Hormon- Und Stoffwechselforschung = Hormones Et Metabolisme|June 30, 2020
Is There a Role for Environmental and Metabolic Factors Predisposing to Severe COVID-19?Stefan R Bornstein, Karin Voit-Bak, Dieter Schmidt, et al.
Journal of Clinical Apheresis|March 1, 2019
Real-world study: Escalating targeted lipid-lowering treatment with PCSK9-inhibitors and lipoprotein apheresisRalf Spitthöver, Tilmann Röseler, Ulrich Julius, et al.
Hormone and Metabolic Research = Hormon- Und Stoffwechselforschung = Hormones Et Metabolisme|January 9, 2025
Neutrophil Extracellular Traps (NETs) as a Potential Target for Anti-Aging: Role of Therapeutic ApheresisNatalia Jarzebska, Roman N Rodionov, Karin Voit-Bak, et al.
European Heart Journal|February 21, 2026
Pelacarsen and lipoprotein(a) apheresis in secondary prevention: the Lp(a)FRONTIERS APHERESIS trialKlaus G Parhofer, Ulrich Julius, Anna Laura Herzog, et al.
Molecular Psychiatry|October 10, 2019
Extracorporeal apheresis therapy for Alzheimer disease-targeting lipids, stress, and inflammationStefan R Bornstein, Karin Voit-Bak, Peter Rosenthal, et al.
Pageof 8

Showing results (61-70 of 76) with videos related to

Sort By:
Pageof 8
Atherosclerosis. Supplements|November 4, 2017
Lipidological competence centres and networks: Future perspectives to improve healthcare of patients with disorders of lipid metabolismFranz Heigl, Tobias Pflederer, Volker Schettler, et al.
Therapeutic Apheresis and Dialysis : Official Peer-Reviewed Journal of the International Society for Apheresis, the Japanese Society for Apheresis, the Japanese Society for Dialysis Therapy|December 5, 2022
The German Lipoprotein Apheresis Registry-Summary of the ninth annual reportVolker J J Schettler, Christian Peter, Thomas Zimmermann, et al.
Hormone and Metabolic Research = Hormon- Und Stoffwechselforschung = Hormones Et Metabolisme|December 12, 2019
Metabolic and Non-Metabolic Peripheral Neuropathy: Is there a Place for Therapeutic Apheresis?Richard Straube, Gregor Müller, Karin Voit-Bak, et al.
Journal of Clinical Lipidology|June 3, 2017
Toward an international consensus-Integrating lipoprotein apheresis and new lipid-lowering drugsClaudia Stefanutti, Ulrich Julius, Gerald F Watts, et al.
Arteriosclerosis, Thrombosis, and Vascular Biology|July 16, 2016
Lipoprotein Apheresis for Lipoprotein(a)-Associated Cardiovascular Disease: Prospective 5 Years of Follow-Up and Apolipoprotein(a) CharacterizationEberhard Roeseler, Ulrich Julius, Franz Heigl, et al.
Hormone and Metabolic Research = Hormon- Und Stoffwechselforschung = Hormones Et Metabolisme|June 30, 2020
Is There a Role for Environmental and Metabolic Factors Predisposing to Severe COVID-19?Stefan R Bornstein, Karin Voit-Bak, Dieter Schmidt, et al.
Journal of Clinical Apheresis|March 1, 2019
Real-world study: Escalating targeted lipid-lowering treatment with PCSK9-inhibitors and lipoprotein apheresisRalf Spitthöver, Tilmann Röseler, Ulrich Julius, et al.
Hormone and Metabolic Research = Hormon- Und Stoffwechselforschung = Hormones Et Metabolisme|January 9, 2025
Neutrophil Extracellular Traps (NETs) as a Potential Target for Anti-Aging: Role of Therapeutic ApheresisNatalia Jarzebska, Roman N Rodionov, Karin Voit-Bak, et al.
European Heart Journal|February 21, 2026
Pelacarsen and lipoprotein(a) apheresis in secondary prevention: the Lp(a)FRONTIERS APHERESIS trialKlaus G Parhofer, Ulrich Julius, Anna Laura Herzog, et al.
Molecular Psychiatry|October 10, 2019
Extracorporeal apheresis therapy for Alzheimer disease-targeting lipids, stress, and inflammationStefan R Bornstein, Karin Voit-Bak, Peter Rosenthal, et al.
Pageof 8